For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 0 | 1,986 | 2,302 | 1,788 |
| Research and development | 25,745 | 20,141 | 15,565 | 14,946 |
| General and administrative | 8,279 | 8,598 | 8,158 | 7,902 |
| Impairment of long-lived assets | 0 | - | - | 4,838 |
| Total operating expenses | 34,024 | 28,739 | 23,723 | 27,686 |
| Loss from operations | -34,024 | -26,753 | -21,421 | -25,898 |
| Change in fair value of warrant liability | 292 | 273 | -102 | -75 |
| Change in fair value of term loan | 1,534 | 1,461 | 1,530 | 1,703 |
| Interest income | 3,169 | 1,859 | 1,326 | 2,107 |
| Interest expense | 15 | 17 | 19 | 24 |
| Other expense | -37 | -237 | 13 | -81 |
| Total other income, net | 1,291 | -129 | -108 | 374 |
| Net loss | -32,733 | -26,882 | -21,529 | -25,524 |
| Earnings per share, basic, total | -0.09 | -0.09 | -0.08 | -0.1 |
| Earnings per share, diluted, total | -0.09 | -0.09 | -0.08 | -0.1 |
| Weighted average number of shares outstanding, basic, total | 353,309,524 | 297,988,978 | 269,306,331 | 267,824,045 |
| Weighted average number of shares outstanding, diluted, total | 353,309,524 | 297,988,978 | 269,306,331 | 267,824,045 |
Taysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc. (TSHA)